Avidity Biosciences
RNA
$24.36
Share price
2.22%
Change (1 day)
67.42%
Change (1 year)
Categories
Avidity Biosciences (RNA) - P/B ratio
P/B ratio as of April 2024 : 3.88
According to Avidity Biosciences's latest financial reports the company has a price-to-book ratio of 3.88.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Avidity Biosciences - P/B ratio (from 2020 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 1.43 | -43.91% |
| 2022-12-31 | 2.55 | -12.7% |
| 2021-12-31 | 2.92 | -6.55% |
| 2020-12-31 | 3.13 | |
| 2019-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.61 | -58.55% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 5.16 | 32.96% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | 14.2 | 265.23% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | -2.68 | -169.03% | 🇺🇸 USA |
 Fate Therapeutics
FATE | 1.18 | -69.75% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | 0.0139 | -99.64% | 🇺🇸 USA |
 Catalyst Pharmaceuticals CPRX | 4.53 | 16.63% | 🇺🇸 USA |